skip to main content

Rogel Cancer Center attends ASCO's annual meeting

Date Visible: 
05/24/2023 - 3:30pm

Media contact: Anna Megdell, 734-764-2220 |  Patients may contact Cancer AnswerLine 800-865-1125

ASCO annual meeting banner for 2023Courtesy ASCO

Rogel Cancer Center faculty and trainees will lead two dozen presentations, posters and moderated sessions at the American Society for Clinical Oncology annual meeting. This year’s meeting will be held in-person and online.

Check out the list of U-M presenters to support your colleagues. Connect with researchers on Twitter using #ASCO23. Be sure to tag @UMRogelCancer.

Presenter information is sometimes incomplete. If your session is missing, please email the abstract link to [email protected].

*All times are in EDT*

June 2

Recurrent and Metastatic Thyroid Cancer: When and Where do we Start?
Maria Papaleontiou, presenter
2:15 - 2:30 PM

Biomarkers of the Future: New Strategies to Predict Sarcoma Outcomes
3:45 - 5:15 PM
Rashmi Chugh, Chair

Navigating Retroperitoneal Sarcoma: Twists, Turns, and Challenges Ahead
Christina Angeles, Presenter
5:45 - 6:25 PM


June 3

Poster Session 9:00 AM

Enhancing STING activation by cyclic dinucleotide-manganese particles for systemic cancer immunotherapy.
James Moon
Abstract: 2571
Poster: 413

Poster Session 2:15 PM

Variations in the approach to lung metastases in osteosarcoma among pediatric and adult patients.
Presenter: Victoria A Wytiaz, M.D., M.A.
Abstract: 11528
Poster: 462

Estimated life-years gained and resultant cost savings from follow-up colonoscopy after a positive multi-target stool DNA (mt-sDNA) test for colorectal cancer screening in commercially insured and Medicare populations.
Presenter: A. Mark Fendrick, M.D.
Abstract: 6642
Poster: 134

Genetic testing into survivorship after diagnosis of breast cancer
Presenter: Steven Katz, M.D., M.P.H.
Abstract: 10583
Poster: 216


June 4

Knowing the Unknown: The Future of Prognostic Tools in Melanoma
9:00 – 10:15 AM
Michael S. Sabel, Chair

Highlights of the Day Session #1
Norah Henry, Presenter
9:15 – 10:30 AM
Hall D1

Measuring and Acting Upon Financial Toxicity Through Cancer Care Delivery Research
9:30 - 9:45 AM
Ruth C. Carlos, Presenter

Who and When: Optimizing HER2+ Therapy to Achieve Exceptional Response
12:30 - 12:42 PM
Anne F. Schott, Discussant
Hall D2

Professional Development and Education Advances
12:30 – 2:00 PM
Gregory Kalemkerian, Chair

Mentorship and Career Development Roundtable: A Discussion With ASCO’s Special Award Recipients
11:00 AM – 12:00 PM
Lori J. Pierce, Chair

Lung Cancer—Non-Small Cell Metastatic
5:30 – 7:00 PM
Angel Qin, Chair
Hall D1

Poster Session 9:00 AM

Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.
Erin Cobain
Abstract: 1076
Poster: 297

Poster Session 2:15 PM

Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
Hannah Dysinger McLaughlin
Abstract: 5552
Poster: 247


June 5

Science of Oncology Award and Lecture
10:45 – 11:30 AM
Lori J. Pierce, Chair

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
12:30 – 2:00 PM
Patrick William Burke, Chair

Addressing Grief, Burnout, and Well-Being in the Practice of Oncology
12:30 – 1:30 PM
Christopher Friese, Presenter

Down the Yellow Brick Road: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
Leslie Anne Fecher, Chair and Presenter
2:00 – 3:15 PM

Germline genetic testing use and results after a cancer diagnosis
4:12 – 4:24 PM
Steven Katz, senior author

Prevention, Risk Reduction, and Hereditary Cancer
4:48 - 5:00 PM
Erin Cobain, Abstracts Discussion

Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.
5:30 - 7:00 PM
Paul Swiecicki, Presenter

Poster Session 9:00 AM

Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.
Yasmin Karimi, M.D.
Abstract: 7525
Poster: 76

Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
Vaibhav Sahai, MBBS, M.S.
Abstract: 4113
Poster: 434

Poster Session 2:15 PM

Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
Hannah Dysinger McLaughlin
Abstract: 5552
Poster: 247

Risk of severe toxicity from topical fluoropyrimidine treatment in patients carrying DPYD variant alleles.
Javier Granados
Abstract: 12123
Poster: 491